Request Demo
Pharmaceutical Insights
Navigate pharmaceutical trends with our insights on targets, institutional pipelines, clinical advances, and new drugs.
Recent blog posts
Latest Hotspot
8 min read
NCT07535489 IPG-11406 Ulcerative colitis, active moderate Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
13 August 2026
NCT07535489 clinical trial report covering IPG-11406, Phase 2, endpoints, sponsor, geography, readout timing and development white space.
Latest Hotspot
8 min read
ChiCTR2600122925 Pucotenlimab Locally Advanced Esophageal Squamous Cell Carcinoma Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
13 August 2026
ChiCTR2600122925 clinical trial report covering Pucotenlimab, Phase 2, endpoints, sponsor, geography, readout timing and development white space.
Latest Hotspot
8 min read
ChiCTR2600122865 Romiplostim Hematologic Neoplasms Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
13 August 2026
ChiCTR2600122865 clinical trial report covering Romiplostim, Phase 2, endpoints, sponsor, geography, readout timing and development white space.
Latest Hotspot
8 min read
NCT07540533 Toripalimab HER2-negative breast cancer Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
13 August 2026
NCT07540533 clinical trial report covering Toripalimab, Phase 2, endpoints, sponsor, geography, readout timing and development white space.
Latest Hotspot
8 min read
NCT07538271 Anlotinib Dihydrochloride Extensive stage Small Cell Lung Cancer Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
13 August 2026
NCT07538271 clinical trial report covering Anlotinib Dihydrochloride, Phase 2, endpoints, sponsor, geography, readout timing and development white space.
Latest Hotspot
8 min read
NCT07538258 Anlotinib Dihydrochloride Small cell lung cancer limited stage Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
13 August 2026
NCT07538258 clinical trial report covering Anlotinib Dihydrochloride, Phase 2, endpoints, sponsor, geography, readout timing and development white space.
Latest Hotspot
8 min read
NCT07538635 Axicabtagene Ciloleucel Large B-cell lymphoma Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
13 August 2026
NCT07538635 clinical trial report covering Axicabtagene Ciloleucel, Phase 2, endpoints, sponsor, geography, readout timing and development white space.
Latest Hotspot
8 min read
NCT07539311 Rinatabart Sesutecan Gastrointestinal Neoplasms Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
13 August 2026
NCT07539311 clinical trial report covering Rinatabart Sesutecan, Phase 2, endpoints, sponsor, geography, readout timing and development white space.
![ISRCTN15647953 [18F]Aldoview Hyperaldosteronism Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook](https://synapse-static.patsnap.com/strapi-static/Blog_cover_B_86_48077a7b89.jpg)
Latest Hotspot
8 min read
ISRCTN15647953 [18F]Aldoview Hyperaldosteronism Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
13 August 2026
ISRCTN15647953 clinical trial report covering [18F]Aldoview, Phase 2, endpoints, sponsor, geography, readout timing and development white space.
Latest Hotspot
8 min read
NCT07539805 Sertraline Hydrochloride Depressive Disorder, Major Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
13 August 2026
NCT07539805 clinical trial report covering Sertraline Hydrochloride, Phase 2, endpoints, sponsor, geography, readout timing and development white space.
Latest Hotspot
8 min read
NCT07538336 Emapalumab-LZSG Transplanted Lung Complication Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
13 August 2026
NCT07538336 clinical trial report covering Emapalumab-LZSG, Phase 2, endpoints, sponsor, geography, readout timing and development white space.
Latest Hotspot
8 min read
NCT07539753 Dalpiciclib Isethionate HR Positive/HER2 Negative/Node positive breast cancer Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
13 August 2026
NCT07539753 clinical trial report covering Dalpiciclib Isethionate, Phase 2, endpoints, sponsor, geography, readout timing and development white space.